Literature DB >> 3355982

Multiple reoperations in recurrent colorectal carcinoma. An analysis of morbidity, mortality, and survival.

A Sardi1, J P Minton, C Nieroda, B Sickle-Santanello, D Young, E W Martin.   

Abstract

Fifty-eight patients in an existing prospective study were evaluated to determine if multiple reoperations for recurrent colorectal carcinoma extended survival. All patients had at least three major operative procedures. The median survival from first, second, third, fourth, and fifth recurrence was 29.9, 17.3, 16, 12.3, and 7.2 months, respectively. The median postoperative hospital stay was 11 days, with a range of 1 to 96 days. The major complication rate was 17%. Twenty-one patients are still alive 19 to 140 months from diagnosis (mean, 50.3 months), 9 to 125 months from the first recurrence (mean, 31.1 months), and 5 to 109 months (mean, 22 months) from the second recurrence. Eleven patients have no evidence of disease. Reoperation for recurrent colorectal carcinoma can be done with acceptable morbidity and mortality and an increase in survival.

Entities:  

Mesh:

Year:  1988        PMID: 3355982     DOI: 10.1002/1097-0142(19880501)61:9<1913::aid-cncr2820610932>3.0.co;2-y

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Complex pattern of colon cancer recurrence including a kidney metastasis: a case report.

Authors:  Helfried Waleczek; Moritz-N Wente; Jürgen Kozianka
Journal:  World J Gastroenterol       Date:  2005-09-21       Impact factor: 5.742

2.  Radiolabeled antibody imaging in the management of colorectal cancer. Results of a multicenter clinical study.

Authors:  R J Doerr; H Abdel-Nabi; D Krag; E Mitchell
Journal:  Ann Surg       Date:  1991-08       Impact factor: 12.969

3.  Pathological complete response following neoadjuvant radiotherapy and intraperitoneal perfusion chemotherapy for recurrent colon carcinoma: A case report and literature review.

Authors:  Xinyu Bian; Baorui Liu; Yang Yang
Journal:  Oncol Lett       Date:  2016-03-02       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.